RxDoctor Payments Data

Stephanie Berg, MD

Internal Medicine · Frisco, TXNPI 1629047659

Payments from drug & device makers

$14,596in general payments, 2019–2025

Across 619 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Currax Pharmaceuticals LLC$3K
  • AbbVie$3K
  • Lilly USA, LLC$669
  • Abbott$518
  • AstraZeneca$480
  • plus $5K from 53 others

What the payments were for

  • Consulting fees$640%
  • Speaking & faculty fees$2,48017%
  • Food & beverage$12,02982%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,596 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$101,193
Medicare patients
302
Services billed
1,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$110,596
JardianceEmpagliflozin29$44,236
MounjaroTirzepatide24$35,422
Tresiba Flextouch U-200Insulin Degludec11$11,810
Hysingla ErHydrocodone Bitartrate11$7,378
BelsomraSuvorexant11$6,511
SynthroidLevothyroxine Sodium28$3,267
Omeprazole76$2,103
Doxepin Hcl11$1,713
Levothyroxine Sodium201$1,655
Duloxetine Hcl73$1,550
Estradiol49$1,519
ValacyclovirValacyclovir Hcl14$1,223
Bupropion XlBupropion Hcl45$1,099
Gabapentin66$1,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,797$110,59678 claims
Boehringer IngelheimJardiance$216$44,23629 claims
Lilly USA, LLCMounjaro$669$35,42224 claims
MerckBelsomra$116$6,51111 claims
AbbVieSynthroid$2,600$3,26728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →